Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment

International audiencePurposeThe optimal treatment duration for ventilator-associated pneumonia is based on one study dealing with late-onset of the condition. Shortening the length of antibiotic treatment remains a major prevention factor for the emergence of multiresistant bacteria.ObjectiveTo demonstrate that 2 different antibiotic treatment durations (8 versus 15 days) are equivalent in terms of clinical cure for early-onset ventilator-associated pneumonia.MethodsRandomized, prospective, open, multicenter trial carried out from 1998 to 2002.MeasurementsThe primary endpoint was the clinical cure rate at day 21. The mortality rate was evaluated on days 21 and 90.Results225 patients were included in 13 centers. 191 (84.9%) patients were cured: 92 out of 109 (84.4%) in the 15 day cohort and 99 out of 116 (85.3%) in the 8 day cohort (difference = 0.9%, odds ratio = 0.929). 95% two-sided confidence intervals for difference and odds ratio were [−8.4% to 10.3%] and [0.448 to 1.928] respectively. Taking into account the limits of equivalence (10% for difference and 2.25 for odds ratio), the objective of demonstrative equivalence between the 2 treatment durations was fulfilled. Although the rate of secondary infection was greater in the 8 day than the 15 day cohort, the number of days of antibiotic treatment remained lower in the 8 day cohort. There was no difference in mortality rate between the 2 groups on days 21 and 90.ConclusionOur results suggest that an 8-day course of antibiotic therapy is safe for early-onset ventilator-associated pneumonia in intubated patients

Prise en charge des nausées et vomissements chimio-induits

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Mobilisation de cellules souches hématopoïétiques avant autogreffe (Facteurs de succès et intérêt du plérixafor)

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Chimiothérapie adjuvante du cancer du sein (incidence et facteurs explicatifs des réductions de dose-intensité)

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Traitement des nausées et vomissements induits par les chimiothérapies anticancéreuses chez l'adulte

DIJON-BU Médecine Pharmacie (212312103) / SudocSudocFranceF

La borréliose de Lyme (position et attitudes pratiques du pharmacien d'officine)

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Bon usage des médicaments anticancéreux (quelle définition ? quels niveaux de preuves scientifiques ?)

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Dix années d'évolution de prise en charge du cancer du sein métastasique (impact clinique et économique)

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Prise en charge et suivi du patient asthmatique à l'officine

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF

Evaluation médico-économique de l'évolution de prise en charge des lymphomes B diffus à grandes cellules de 1995 à 2008 au CHRU de Besançon

BESANCON-BU Médecine pharmacie (250562102) / SudocSudocFranceF